In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). (Q38035808)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2012

Language	Label	Description	Also known as
English	In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).	scientific article published on September 2012

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). (English)

1 reference

Europe PubMed Central

27 August 2017

Streptococcus pneumoniae

1 reference

based on heuristic

inferred from title

multiple drug resistance

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

Mariana Castanheira

2

object named as

Mariana Castanheira

1 reference

Europe PubMed Central

27 August 2017

4

object named as

Helio S Sader

1 reference

Europe PubMed Central

27 August 2017

5

object named as

Ronald N Jones

1 reference

Europe PubMed Central

27 August 2017

Rodrigo E. Mendes

3

object named as

Rodrigo E Mendes

1 reference

Europe PubMed Central

27 August 2017

author name string

David J Farrell

1

1 reference

Europe PubMed Central

27 August 2017

language of work or name

0 references

publication date

1 September 2012

1 reference

Europe PubMed Central

27 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

27 August 2017

55 Suppl 3

1 reference

Europe PubMed Central

27 August 2017

S206-14

1 reference

Europe PubMed Central

27 August 2017

Emergence of antibiotic-resistant bacteria

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

A SURVEY OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS AUREUS.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Recruitment of the mecA gene homologue of Staphylococcus sciuri into a resistance determinant and expression of the resistant phenotype in Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

The changing epidemiology of resistance

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Penicillin-binding proteins and beta-lactam resistance

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Ceftaroline: a comprehensive update

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Diversity and evolution of blaZ from Staphylococcus aureus and coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS563

21 January 2018

Identifiers

10.1093/CID/CIS563

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38035808&oldid=1940516921"